Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...
The BRAVE-AA-PEDS trial found that once-daily baricitinib significantly improved hair regrowth on the scalp, eyebrows, and ...
The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...
The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...
Leerink Partners 2025 Global Healthcare Conference Call March 12, 2025 11:20 AM ETCompany ParticipantsRoland Chen ...
Treatment with deucravacitinib in patients with active PsA showed higher response rates and improvement in quality of life ...
Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...
The market slump continued yesterday as President Donald Trump's "period of transition" fuels stagflation fears. It led to ...
Investor's Business Daily on MSN4d
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks OutProtagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study.
Bristol Myers Squibb's Phase 3 POETYK PsA-2 trial shows Sotyktu improved psoriatic arthritis symptoms, meeting primary and secondary endpoints at Week 16.
On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback